By Dow Jones Business News,
May 09, 2014, 06:15:00 PM EDT
By Maria Armental
A potential treatment for moderate-to-severe plaque psoriasis shows positive results, Amgen Inc. ( AMGN ) and
AstraZeneca PLC ( AZN ) said Friday.
The drug makers said the Phase 3 of the brodalumab 661-patient study met all primary and secondary endpoints,
including patients achieving at least 75% improvement from baseline in disease severity or clear or almost clear skin at
Adverse effects included nasopharyngitis, upper respiratory tract infections and headaches. Serious adverse effects
occurred in 1.8% of patients in the higher dose group studied and 2.7% of the lower dose, compared to 1.4% for the
Plaque psoriasis is the most common form of psoriasis, a non-contagious, autoimmune chronic disease in which skin
cells grow at an accelerated rate, causing painful and itchy, red, scaly patches.
Brodalumab is a novel human monoclonal antibody that binds to the interleukin-17 (IL-17) receptor and inhibits
inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor, the drug makers said.
In addition to moderate-to-severe plaque psoriasis, Amgen and AstraZeneca are studying the use of brodalumab to treat
psoriatic arthritis (Phase 3) and asthma (Phase 2).
The companies are developing and commercializing five monoclonal antibodies from Amgen's clinical inflammation
portfolio, including brodalumab, under an April 2012 agreement.
Shares of Amgen closed at $111.48 Friday and were slightly up in after-hours trading. ZastraZeneca's shares, also up
in after-hours trading, closed at $77.24.
Write to Maria Armental at email@example.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
Copyright (c) 2014 Dow Jones & Company, Inc.